Clinical Trials, Phase II as Topic

"Clinical Trials, Phase II as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.

Descriptor ID	D017322
MeSH Number(s)	E05.318.760.250.500.210 N05.715.360.775.088.500.210 N06.850.520.450.250.250.210
Concept/Terms	Clinical Trials, Phase II as Topic Clinical Trials, Phase II as Topic Evaluation Studies, FDA Phase II as Topic Evaluation Studies, FDA Phase II as Topic Evaluation Studies, FDA Phase 2 as Topic Drug Evaluation, FDA Phase II as Topic Drug Evaluation, FDA Phase II as Topic Drug Evaluation, FDA Phase 2 as Topic

Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase II as Topic".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Epidemiologic Methods [E05.318]
Epidemiologic Study Characteristics [E05.318.760]
Clinical Studies as Topic [E05.318.760.250]
Clinical Trials as Topic [E05.318.760.250.500]
Clinical Trials, Phase II as Topic [E05.318.760.250.500.210]
Health Care [N]
Health Care Quality, Access, and Evaluation [N05]
Quality of Health Care [N05.715]
Health Care Evaluation Mechanisms [N05.715.360]
Epidemiologic Study Characteristics [N05.715.360.775]
Clinical Studies as Topic [N05.715.360.775.088]
Clinical Trials as Topic [N05.715.360.775.088.500]
Clinical Trials, Phase II as Topic [N05.715.360.775.088.500.210]
Environment and Public Health [N06]
Public Health [N06.850]
Epidemiologic Methods [N06.850.520]
Epidemiologic Study Characteristics [N06.850.520.450]
Clinical Studies as Topic [N06.850.520.450.250]
Clinical Trials as Topic [N06.850.520.450.250.250]
Clinical Trials, Phase II as Topic [N06.850.520.450.250.250.210]

Below are MeSH descriptors whose meaning is related to "Clinical Trials, Phase II as Topic".

Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase II as Topic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Clinical Trials, Phase II as Topic" by people in this website by year, and whether "Clinical Trials, Phase II as Topic" was a major or minor topic of these publications.

Bar chart showing 74 publications over 28 distinct years, with a maximum of 7 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1997	0	1	1
1999	0	1	1
2000	0	1	1
2001	0	1	1
2002	0	1	1
2003	0	1	1
2004	0	6	6
2005	1	3	4
2006	0	1	1
2007	0	1	1
2008	0	4	4
2009	0	3	3
2010	1	3	4
2011	0	1	1
2012	0	3	3
2013	1	3	4
2014	1	3	4
2015	0	1	1
2016	0	1	1
2017	0	1	1
2018	2	2	4
2019	1	2	3
2020	0	7	7
2021	1	3	4
2022	0	3	3
2023	0	2	2
2024	0	6	6

Below are the most recent publications written about "Clinical Trials, Phase II as Topic" by people in Profiles.

Peterlin BL, Bond DS, Ailani J, Dodick DW, Liu Y, De Abreu Ferreira R, Smith JH, Dabruzzo B, Goadsby PJ, Trugman JM. Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis. Cephalalgia. 2024 12; 44(12):3331024241299753.

View in: PubMed
Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Kl?mpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Komatsu Y, Ahn DH, Epstein RS, Halim AB, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA. Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer. Future Oncol. 2024; 20(36):2811-2822.

View in: PubMed
Nicol? E, Gandini S, Giugliano F, Uliano J, D'Ecclesiis O, Morganti S, Ferraro E, Trapani D, Tarantino P, Zagami P, Boldrini L, Caramella I, Carnevale Schianca A, Cristofanilli M, Locatelli MA, Esposito A, Belli C, Minchella I, Criscitiello C, Marra A, Curigliano G. Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials. Eur J Cancer. 2024 Aug; 207:114181.

View in: PubMed
Azad N, Hu Z, Sahin I, Iyer R, Aranha O, Hochster H, Pathak P, Paulson AS, Kalyan A, Liao CY, Tran N, Kelley RK, Heestand G, Cosgrove D, El-Khoueiry A, Borad M, Gabrail NY, Majeed U, Du L, Kamath S, Shumway N, Shroff R, Goyal L, Rosales M, Javle M. COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC. Future Oncol. 2024; 20(30):2241-2248.

View in: PubMed
Kulkarni T, Criner GJ, Kass DJ, Rosas IO, Scholand MB, Dilling DF, Summer R, Duncan SR. Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis. BMC Pulm Med. 2024 Mar 20; 24(1):143.

View in: PubMed
Tassorelli C, Onishchenko K, Halker Singh RB, Duan M, Dupont-Benjamin L, Hemstock M, Voller C, McAllister P, Nahas SJ, Gandhi P, Ailani J. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. Cephalalgia. 2024 02; 44(2):3331024241235156.

View in: PubMed
Surkar SM, Willson JD, Cassidy JM, Kantak S, Patterson CG. Remote ischaemic conditioning combined with bimanual task training to enhance bimanual skill learning and corticospinal excitability in children with unilateral cerebral palsy: a study protocol of a single centre, phase II randomised controlled trial. BMJ Open. 2023 09 28; 13(9):e076881.

View in: PubMed
Geskin LJ, Angello JT, Bagot M, Guenova E, Nikbakht N, Querfeld C, Scarisbrick JJ. Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facilitate Optimal Treatment Experiences. Clin Lymphoma Myeloma Leuk. 2024 01; 24(1):40-47.

View in: PubMed
Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, Bauman J, Casanova M, Krishnamurthy A, Kummar S, Leyvraz S, Oh DY, Park K, Sohal D, Sherman E, Norenberg R, Silvertown JD, Brega N, Hong DS, Cabanillas ME. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022 Apr 29; 186(6):631-643.

View in: PubMed
Jacobson G, Fluss R, Dany-BenShushan A, Golan T, Meron T, Zimmermann C, Dawson LA, Barry A, Miszczyk M, Buckstein M, Diaz Pardo D, Aguiar A, Hammer L, Dicker AP, Ben-Ailan M, Morag O, Hausner D, Symon Z, Lawrence YR. Coeliac plexus radiosurgery for pain management in patients with advanced cancer : study protocol for a phase II clinical trial. BMJ Open. 2022 03 24; 12(3):e050169.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement